<乌鸦传媒>Another COVID-19 Side Effect: 'Zoom Dysmorphia' As people spend more time on camera, many of them like themselves less and less May 06, 2021
<乌鸦传媒>First Detailed Look at COVID Vaccine Skin Reactions Mostly mild, self-limiting reactions and no serious adverse reactions May 05, 2021
<乌鸦传媒>Rapid Improvement in Atopic Dermatitis With New JAK1 Inhibitor Plus: First-in-class drug shows promise in AD, BTK inhibitor active in pemphigus May 03, 2021
<乌鸦传媒>Topical JAK Inhibitor Shows Promise in Vitiligo Half of patients had 90% improvement after 2 years of treatment Apr 30, 2021
<乌鸦传媒>High Rate of Hyperhidrosis Relief With Topical Agent Benefit for 86% of patients treated with sofpironium bromide Apr 29, 2021
<乌鸦传媒>Rapid Improvement in Atopic Dermatitis With Topical JAK Inhibitor Disease activity index improved as early as week 1 with delgocitinib cream Apr 27, 2021
<乌鸦传媒>Significant Improvement in Hand Eczema With Pan-JAK Inhibitor Disease activity indicators reduced, no safety signals with gusacitinib versus placebo Apr 26, 2021
<乌鸦传媒>Drug 'TYKs' All the Boxes in Two Plaque Psoriasis Trials Significantly higher response rates with TYK2 inhibitor deucravacitinib versus apremilast Apr 25, 2021
<乌鸦传媒>Big Win in Psoriasis for Dual IL-17A/17F Inhibitor Significant differences in clearance with bimekizumab vs secukinumab at all time points Apr 23, 2021
<乌鸦传媒>Op-Ed: Dermatology Needs Lower Costs and Better Care A proposal for value-based care Apr 21, 2021
<乌鸦传媒>Nivolumab Alone Prevails in Resected Melanoma Adding ipilimumab in adjuvant setting failed to improve relapse-free survival Apr 11, 2021
<乌鸦传媒>For Enthesitis in Psoriatic Arthritis, Target IL-23 Targeted agent provides relief for many PsA patients Apr 08, 2021
<乌鸦传媒>COVID Triggers Novel Infectious Skin Condition in Teen Mild case led to unusual effects a week later Apr 07, 2021
<乌鸦传媒>JAK Inhibitor Promising in Psoriatic Arthritis Oral agent noninferior to adalimumab in joint symptoms Apr 01, 2021
<乌鸦传媒>A Win for Adjuvant Immunotherapy in Esophageal Cancer And other highlights from the Society of Surgical Oncology's virtual 2021 meeting Mar 31, 2021
<乌鸦传媒>Don't Stop Taltz in Psoriatic Arthritis Significantly more patients relapsed, and more quickly, after withdrawal Mar 10, 2021
<乌鸦传媒>Using the Skin Microbiome to Control Atopic Dermatitis Bacteria-based therapy shows promise in proof-of-concept trial Mar 01, 2021
<乌鸦传媒>Young Hidradenitis Suppurativa Patients See Lags in Care Diagnosis typically came years after disease onset; providers claim lack of knowledge on HS pain Feb 24, 2021
<乌鸦传媒>Want Data on Recently Approved Actinic Keratosis Drug? Here You Go Phase III trial now published in full for topical anti-proliferative treatment Feb 10, 2021
<乌鸦传媒>First Immunotherapy Approved for Basal Cell Carcinoma Objective responses in 27% of previously treated patients who received cemiplimab Feb 10, 2021
<乌鸦传媒>Monoclonal Antibody Highly Effective in Phase III Psoriasis Trial Beats ustekinumab, but main side effect was oral candidiasis Feb 05, 2021
<乌鸦传媒>Brain Tumor Risk Upped With Synthetic Progestogen Absolute risk still low, however, and product not currently approved in U.S. Feb 03, 2021
<乌鸦传媒>High Potassium No Threat With Spironolactone Despite guidelines, many still monitoring K levels in young women with acne, researchers find Jan 27, 2021
<乌鸦传媒>Masculinizing Hormone Therapy Tied to Acne in Transmen Acne also linked with depression and anxiety; Accutane may be treatment option Jan 20, 2021
<乌鸦传媒>Op-Ed: Gym for Surgeons? To perform like athletes, surgeons need to train like athletes Dec 26, 2020
<乌鸦传媒>Derm Symptoms Signal MIS-C in Kids Case series shows mucocutaneous findings in most children Dec 09, 2020
<乌鸦传媒>Renewed Concerns About Finasteride and Mental Health Database study links popular alopecia treatment with increased risks of suicidality, depression Nov 27, 2020
<乌鸦传媒>More Evidence for Ligelizumab in Chronic Hives Anti-IgE drug showed improved activity in omalizumab-treated patients with inadequate symptom control Nov 17, 2020
<乌鸦传媒>IL-8 Antibody Active in Tumors After PD-1/L1 Blockade Clinical benefit in more than a third of patients with anti-IL-8/nivolumab combo Nov 13, 2020
<乌鸦传媒>PD-1 Inhibitor Active in Progressive Basal Cell Cancer Response rate of 20-30% with cemiplimab after post-hedgehog inhibitor progression or intolerance Nov 11, 2020
<乌鸦传媒>Watch for Suicidality in Men on Propecia Analysis found high number of psychological-related reports Nov 11, 2020
<乌鸦传媒>TYK2 Inhibition Promising in Psoriatic Arthritis Phase II study found significant benefits for two doses of novel agent Nov 10, 2020
<乌鸦传媒>Gut Bacteria for Psoriasis; Long-Term Hair Growth; COVID and STDs Selected presentations from the European Academy of Dermatology and Venereology virtual conference Nov 05, 2020
<乌鸦传媒>Nonsteroidal Topical, Nanodrug Active in Psoriasis Selected presentations from the European Academy of Dermatology and Venereology meeting Nov 04, 2020
<乌鸦传媒>Atopic Dermatitis: New Topical Agent, Durable Results With Orals Selected abstracts from the European Academy of Dermatology and Venereology Virtual Conference Nov 02, 2020
<乌鸦传媒>First-Ever Positive Phase III Trial in Epidermolysis Bullosa Faster wound healing with oleogel-S10, particularly in most common form of EB Nov 01, 2020
<乌鸦传媒>Add Skin Conditions to COVID-19 Long-Hauler Effects Persistence beyond 60 days in some cases, especially with pernio/chilblains Oct 30, 2020
<乌鸦传媒>Melanoma Survival Benefit Sustained at 5 Years With Adjuvant Combo Dabrafenib plus trametinib cut relapse risk in half Sep 02, 2020
